Filter Results:
(524)
Show Results For
- All HBS Web
(524)
- People (2)
- News (136)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(524)
- People (2)
- News (136)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
- 17 Jul 2024
- News
Harvard Business School Announces Its 2024-2025 Blavatnik Fellows
- 2023
- Other Unpublished Work
Visions of Vision Pro
Daily ups and downs of the market are often driven by changes in interest-rate expectations and investor risk aversion. But over the long run, it's often technological change that is the primary driver of value. A decade ago, Tyler Cowen argued in his book The Great... View Details
Cohen, Randolph B. "Visions of Vision Pro." August 2023. (LinkedIn Articles.)
- 11 Apr 2019
- News
The DNA of Sustained Innovation
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details
Keywords: Drug Development; Drug Discovery; Drug Trials; Pharmaceutical Companies; Pharmaceutical Company; Pharmaceuticals; Therapeutics; Biologics; Biotech; Biotechnology; Biopharmacy Company; Biochemistry; Technology Commercialization; Technology Companies; Drug Testing; Startup; Start-up; Startups; Start-ups; Startup Financing; Strategic Decision Making; Strategic Decisions; Strategic Evolution; FDA; Food And Drug Administration; Clinical Trials; Disease Management; Market Attractiveness; Market Entry; Market Opportunities; Health Disorders; Technological Innovation; Information Technology; Commercialization; Business Startups; Finance; Decision Making; Strategy; Market Entry and Exit; Opportunities; Pharmaceutical Industry; Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details
Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Thermo Fisher Scientific: Foray into Contract Research." Harvard Business School Case 824-073, October 2023. (Revised May 2024.)
- April 2009 (Revised October 2010)
- Case
Bob Beall at the Cystic Fibrosis Foundation
By: Robert Steven Kaplan and Sophie Hood
Bob Beall is the Chief Executive Officer of the Cystic Fibrosis Foundation (CFF). CFF is an extremely successful organization, but Beall has to determine how to manage the organization through the financial crisis of 2008-2009. In this situation, donations are likely... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Philanthropy and Charitable Giving; Governing and Advisory Boards; Leadership; Crisis Management; Nonprofit Organizations
Kaplan, Robert Steven, and Sophie Hood. "Bob Beall at the Cystic Fibrosis Foundation." Harvard Business School Case 409-107, April 2009. (Revised October 2010.)
- March 2024
- Case
Biomanufacturing Decentralization by Stämm
By: Paul A. Gompers, Jenyfeer Martínez Buitrago and Mariana Cal
In Buenos Aires, Argentina, cousins Llamazares and D’Alvia founded Stämm, a startup based on the idea of decentralizing biomanufacturing processes and downsizing biotech facilities. After raising its seed and series A rounds, and while finalizing its series B round in... View Details
Keywords: Business Model; Business Startups; Entrepreneurship; Venture Capital; Selection and Staffing; Technological Innovation; Science-Based Business; Business Strategy; Commercialization; Growth and Development Strategy; Product Launch; Research and Development; Biotechnology Industry; Latin America; South America; Argentina; Buenos Aires
Gompers, Paul A., Jenyfeer Martínez Buitrago, and Mariana Cal. "Biomanufacturing Decentralization by Stämm." Harvard Business School Case 824-190, March 2024.
- September 2013 (Revised November 2015)
- Case
Living Proof: Are We a Technology Company or a Beauty Company?
By: Willy Shih
Jon Flint came up with the idea of a science-based beauty company while talking with his hairdresser about the problems with typical hair and skin care products. Together with a small team that included Professor Robert Langer of MIT, he committed to assemble a team... View Details
Keywords: Hair Care; Personal Care; Science-based; R&D; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Marketing; Marketing Strategy; Product Marketing; Product Positioning; Science-Based Business; Business Strategy; Commercialization; Corporate Strategy; Technology Platform; Expansion; Beauty and Cosmetics Industry; United States; Boston; Cambridge
Shih, Willy. "Living Proof: Are We a Technology Company or a Beauty Company?" Harvard Business School Case 614-013, September 2013. (Revised November 2015.)
- June 2021
- Case
uBiome
By: Thomas R. Eisenmann and Olivia Graham
uBiome provided clinical tests that sequenced the DNA of human microbiome samples, providing data on health conditions directly to consumers or to prescribing physicians. Founded in 2012, the San Francisco-based startup raised $105 million from top-tier venture capital... View Details
- June 2013
- Article
Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration
By: Umit Ozmel, Jeffrey J. Reuer and Ranjay Gulati
In this paper, we examine the contingent effects of signals generated by different types of networks on new ventures' formation of future strategic alliances. We argue that the signaling value of a given tie in reducing adverse selection is more pronounced when another... View Details
Ozmel, Umit, Jeffrey J. Reuer, and Ranjay Gulati. "Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration." Academy of Management Journal 56, no. 3 (June 2013): 852–866.
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Pharmaceutical Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- February 2006
- Case
Michelle Levene (A)
Michelle Levene discovers that she is pregnant a few days before receiving an offer for her dream job. The new position would require Levene to travel extensively, something she would not be able to do towards the end of the pregnancy and while caring for a newborn.... View Details
Keywords: Work-Life Balance
Casciaro, Tiziana E., and Victoria Winston. "Michelle Levene (A)." Harvard Business School Case 406-083, February 2006.
- January 2006
- Case
Jack Strang at SequenceLabs
By: Mukti Khaire, John J. Gabarro and Lynda M. Applegate
How can entrepreneur manage his firm if things go wrong despite having a great idea, a solid team, and financial backing? Jack Strang founded a biotech firm with his friend Peter Evans, to develop molecular pathway-based "cures" for metabolic disorders. The idea was... View Details
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details
Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry
Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.
- Web
Class Profile - MBA
use a 4.0 grading system) 143 Domestic Universities 153 International Universities Pre-MBA Industry Consulting Consumer Products / Retail / E-Commerce Financial Services Health Care / Biotech Manufacturing / Industrial / Energy Media /... View Details
- August 2010 (Revised January 2013)
- Case
Avi Kremer
By: Joshua D. Margolis and Mark Wetzel
If you were diagnosed with a terminal illness, how would you respond and what would you do with your remaining time? Avi Kremer contemplates four options for how to devote himself 18 months after being diagnosed with ALS. His experience thus far and the choices he... View Details
Keywords: Entrepreneurship; Values and Beliefs; Health Disorders; Leadership Development; Personal Development and Career; Social Enterprise; Personal Characteristics
Margolis, Joshua D., and Mark Wetzel. "Avi Kremer." Harvard Business School Case 411-022, August 2010. (Revised January 2013.)
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- Web
Overview - MBA
students’ existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. Hear from Program Advisors on the impact of this program and the power of the Harvard View Details
- Web
MS/MBA Biotechnology: Life Sciences - MBA
Biotechnology: Life Sciences Program at Harvard University builds upon students’ existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to lead transformative... View Details
- 19 May 2009
- First Look
First Look: May 19, 2009
entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September 2008. The... View Details
Keywords: Martha Lagace